This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Wellcome Fellowship Awarded.
—Ophthalmologist Catherine Newton, MD, who will study the effectiveness of cyclosporine in suppressing corneal graft rejection, has been awarded the Wellcome Research Fellowship in Ophthalmology, administered through the National Society to Prevent Blindness (NSPB).The one-year fellowship, announced jointly by the sponsor, the Burroughs Wellcome Fund, and the NSPB, carries an award of $20,000. This is the second Wellcome Research Fellowship administered through the NSPB.Dr Newton was selected by the NSPB's Committee on Basic and Clinical Research, headed by Steven M. Podos, MD, professor and chairman, Department of Ophthalmology, Mount Sinai School of Medicine, City University of New York.Cyclosporine is a new drug used successfully in preventing rejection of transplanted kidneys, but it does have notable side effects when taken systematically. Dr Newton will investigate the effect of cyclosporine eye drops in corneal graft rejection and determine how to obtain an effective drug level
News and Comment. Arch Ophthalmol. 1984;102(10):1440–1441. doi:10.1001/archopht.1984.01040031160008
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.